KPV vs LL-37
Both KPV and LL-37 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →LL-37
Evidence BCathelicidin LL-37
The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
View full LL-37 profile →Side-by-Side
| Attribute | KPV | LL-37 |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — endogenous antimicrobial peptide; clinical trials for infected wounds |
| Typical Dose | 200–500 mcg orally or topical (research only) | Trial range: topical or intralesional |
| Clinics Indexed | 26 | 19 |
| Categories | anti-inflammatory, gut-health, skin | immune, anti-inflammatory |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — LL-37
- ✓Broad antimicrobial activity
- ✓Wound healing
- ✓Anti-biofilm
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.